AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data from Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate

--Top-line Results Confirming Safety, Liver Transfection Presented at ESGCT Conference--

THE HAGUE, the Netherlands, Oct. 27, 2014 (GLOBE NEWSWIRE) -- The AIPGENE Consortium, a pan-European collaboration supported by the Seventh Framework Programme, and uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced the top-line one year follow-up analysis of a completed Phase I dose-escalation clinical trial testing an AAV5-PBGD gene therapy candidate (AMT-021) in Acute Intermittent Porphyria (AIP) patients. The data were presented on Saturday, October 25, at the European Society of Gene and Cell Therapy (ESGCT) and Netherlands Society of Gene and Cell Therapy (NVGCT) Collaborative Congress by Dr. Gloria González-Aseguinolaza, the Scientific Coordinator of the AIPGENE Consortium. The preliminary analysis of the data confirm the safety and successful transduction of patient's liver cells with the porphobilinogen deaminase gene (PBGD) using uniQure's proprietary AAV5 viral vector, as previously indicated in the interim analysis presented in May 2014.

AIP is a rare and devastating monogenic disease caused by mutations in the PBGD gene. AIP can be life threatening and the long-term effects include irreversible nerve damage, liver cancer and kidney failure. AMT-021 consists of the PBGD gene encapsulated in the AAV5 viral vector and is designed to enable transfection of the PBGD gene into patient's liver cells through a single therapeutic intervention.

"We have gathered critical clinical experience that will contribute greatly to the further understanding of this complex disease," said Dr. González-Aseguinolaza, Director of Gene Therapy and Regulated Expression Programme at the Center for Applied Medical Research (CIMA) of the University of Navarra, Spain.  "I speak for all of the collaboration members in thanking the Seventh Framework Programme for supporting our study and the advancement of a gene therapy approach to help AIP patients."

"The AIPGENE collaboration has achieved its primary goal in completing a successful Phase I study, providing first and foremost the safety data required for additional clinical study," said Dr. Harald Petry, Chief Scientific Officer of uniQure. "uniQure will work with the consortium to complete the final analysis of the data for publication and to define what the next steps for the further development of AMT-021 should be."

In the multicenter, open label, single dose, dose-ranging Phase I clinical trial, a total of eight patients in four dosing cohorts received AMT-021 doses of up to 2 x 10 13 gc/kg. The trial reported no safety concerns from any patient; in particular, there was no evidence of cellular immune response against the AAV5 vector or the PBGD transgene. Humoral responses against AAV5 were detected in all patients, as expected. Vector genomes were detected in patients' liver biopsies obtained one year after vector injection indicating that AMT-021 sustainably transduced human liver cells.

The Phase I trial was conducted by Digna Biotech as part of the AIPGENE Consortium.  In addition to Digna, CIMA and uniQure, the consortium included the Clínica Universidad de Navarra/University of Navarra, Karolinska University Hospital, the National Center for Tumour Diseases, Heidelberg, and Servicio Madrileño de Salud, Madrid.

About AIP

Acute Intermittent Porphyria (AIP) is a rare metabolic liver disorder resulting from mutations in the porphobilinogen deaminase, or PBGD, gene, which encodes for the enzyme involved in the production of heme in the body.  Insufficient activity of this protein leads to an accumulation of toxic metabolites, resulting in a wide variety of serious clinical problems, including acute, severe abdominal pain, muscular weakness and an array of neurologic manifestations, including psychiatric episodes, seizures and coma. In the majority of cases, precipitating factors, such as hormonal fluctuations, infections, drugs and dietary changes, trigger attacks.  Long-term consequences may include irreversible nerve damage, liver cancer and kidney failure.  Patients with AIP experience regular hospitalizations and extremely poor quality of life.  Acute attacks can be life threatening.  Current therapies include intravenous administration of heme and carbohydrate loading, which aim to treat the symptoms only and do not prevent attacks.  In some cases, AIP patients require liver transplants.

About AIPGENE

This Collaborative Project involves seven partners from four different European countries and is related to the theme HEALTH.2010.2.4.4-1: Clinical development of substances with a clear potential as orphan drugs. The AIPGENE project is co-funded by the European Commission within the 7th Framework Programme for Research. The project is coordinated by CIMA, a European Center for Applied Medical Research, and began in 2004. The international team of experts involved in the AIPGENE consortium brings together complementary scientific disciplines to implement a new therapeutic option for AIP patients.

About uniQure

uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com

uniQure:
Aicha Diba Investor Relations
Direct : +31 20 240 6100
Main: +31 20 566 7394
a.diba@uniQure.com

Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +1 781 235 3060
gschweitzer@macbiocom.com

HUG#1865965

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 0

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 222

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 301

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 139

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 49

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading

Top 5 Most Recently Viewed Articles

Breaking News: Sportswear Highlights and Streaming Drama Unfolds

Updated Category News Views 235

New On The Block Puma SE, a Germany-based sportswear company, is drawing interest from several buyers in Asia. Notable bids are coming from China's Anta Sports and Li Ning Co., alongside Japan's Asics Corp. As the market responds to this potential sale, the implications for both Puma and the interested firms may shift the dynamics in the sportswear industry. The Netflix...

Continue Reading
Bridging the AI Adoption Gap for Modern Enterprises

Updated Category News Views 103

Navigating the Challenges of AI Adoption in Enterprises In today's fast-paced business landscape, the integration of artificial intelligence (AI) has become more crucial than ever. A recent survey conducted by Unily highlights a pressing concern: many enterprises are struggling to keep pace with AI adoption. The findings reveal that nearly 40% of employees feel their...

Continue Reading
Cryptocurrency Market Trends: Key Insights on Bitcoin and More

Updated Category News Views 393

Cryptocurrency Market Holds Steady Amid Economic Shifts Recently, the cryptocurrency market has shown remarkable stability despite fluctuating stock indices. As economic factors shift, particularly with recent job data revisions, market expectations for interest rate changes have intensified. Bitcoin Sees Minor Decline Bitcoin momentarily surged past $113,000 before...

Continue Reading
Exploring Earnings Insights for Stantec's Upcoming Report

Updated Category News Views 77

Stantec's Upcoming Earnings Report Overview Stantec (NYSE: STN) is preparing to release its latest quarterly earnings report soon. Investors are gearing up in anticipation of what this report might reveal about the company's financial health and future outlook. Analysts' Earnings Predictions Experts are estimating that Stantec will announce an earnings per share (EPS) of...

Continue Reading
Yarbo Unleashes the M Series: Transforming Yard Care

Updated Category News Views 45

Dust off your lawn chairs, folks, because Yarbo is strutting into IFA 2026 with its M Series, a real game-changer in yard robotics. These aren't just fancy grass clippers; they're smart machines turning yard care on its head. Ever wrestle with a rake or push a lawn mower when you'd rather be soaking in some sun? Well, you're in luck. From Dream to Dirt: M Series Arrives...

Continue Reading